This week in Part 3 of our Case Study, Mr. Walker and his wife return for a follow-up visit as his glucose control has not improved as much as expected. Click here to see if you agree with the drug choice.

In our analysis of the GLP-1 survey data, we take a look at some of your perceptions of GLP-1 Agonists, how they work, and what you think about the side effects and DPP-4 inhibitors.

In addition, Steve and our team of interns have found some late breaking abstracts on GLP-1 agonists from the ADA that you probably won't see anywhere else. And we've included a special feature this week on the Effect of Glp-1 on Cardiovascular Risk Factors.

Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)....

Exenatide yields beta cell improvement and weight loss in individuals with diabetes but has not been well-studied in individuals with prediabetes....

The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes. To investigate the CV profile of the novel DPP-4 inhibitor linagliptin, a pre-specified meta-analysis of all CV events from 8 phase III randomized, double blind, controlled trials (≥12 weeks) was conducted....

Case Presentation, PART 3: Mr. Walker is a 59-year-old Caucasian who presents for evaluation of his type 2 diabetes, discovered 6 months ago by a random glucose measurement of 250 mg/dL using his wife's blood glucose meter. Mr. Walker visited his physician a few days later at his wife's request and had an A1C measurement of 7.5%....

Glucagon-like peptide-1 mimetics improve certain cardiovascular risk factors, although it is unclear if the observed benefits are direct effects or indirect effects due to weight loss....

This week we examine more of your responses regarding GLP-1 therapy....

Each of us -- every human adult -- is composed of roughly 100 trillion individual cells. Our health depends on effective communication between those cells. Over time, it has become clear that the systems that coordinate cellular activity are far more complex than we originally believed....

To help introduce this new series on GLP-1 therapy, we've gathered together commentary and insight from leading experts across the field: Anne L. Peters, MD, Ralph A. DeFronzo, MD, Alan J. Garber, MD, PhD, Robert R. Henry, MD, Richard Bergenstal, MD, and others share their thoughts....

Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia....